The Role of Category III CPT Codes in Facilitating the Adoption and Reimbursement of AI-Driven Diagnostic Technologies in Healthcare

Abstract

The profound integration of artificial intelligence (AI) into the fabric of healthcare diagnostics stands as a pivotal development poised to fundamentally reshape patient care delivery. This transformative potential manifests through enhanced diagnostic accuracy, streamlined operational efficiencies, and expanded accessibility to advanced medical insights. However, the pervasive adoption and sustainable deployment of these sophisticated AI-driven diagnostic tools are inextricably linked to their successful navigation and acceptance within the intricate existing healthcare reimbursement frameworks. This comprehensive research delves into the critical role and multifaceted significance of Category III Current Procedural Terminology (CPT) codes as a primary facilitator for the reimbursement, integration, and eventual widespread clinical utility of nascent AI technologies within contemporary medical practice. Through a meticulous examination of the landmark case of Eko Health’s SENSORA — an innovative AI-powered cardiac diagnostic platform that recently secured a Category III CPT code — this study meticulously explores the broader implications of such strategic coding decisions. These implications extend far beyond mere billing mechanisms, impacting the commercial viability, long-term sustainability, scalability, and equitable access of AI-driven diagnostics across diverse clinical settings, thereby illuminating the pathway for future innovation and adoption in the healthcare ecosystem.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

The global healthcare industry is currently undergoing an unprecedented technological metamorphosis, driven by the rapid advancements and strategic incorporation of artificial intelligence into virtually every facet of diagnostic processes. These groundbreaking innovations hold immense promise, poised to significantly augment clinical decision-making capabilities, substantially reduce the incidence of diagnostic errors, and ultimately achieve demonstrably improved patient outcomes. The capabilities of AI, particularly in analyzing vast, complex datasets, detecting subtle patterns, and generating predictive insights, are already proving invaluable in various medical specialties, from imaging and pathology to cardiology and genomic medicine.

Despite the clear and compelling advantages that AI-driven diagnostics offer, their widespread clinical adoption continues to confront a formidable array of challenges. Paramount among these are the inherent complexities, opacities, and often slow-moving nature of existing healthcare reimbursement policies and standardized medical coding systems. In the United States, the American Medical Association’s (AMA) Current Procedural Terminology (CPT) codes serve as the quintessential standardized language for meticulously reporting medical services, procedures, and interventions performed by healthcare providers. This standardized lexicon plays an absolutely pivotal role, not only in determining the mechanisms and rates of reimbursement from governmental and private payers but also, critically, in facilitating the seamless integration of novel medical technologies and innovative procedures into established clinical practice pathways.

This scholarly paper undertakes an in-depth investigation into the instrumental role of Category III CPT codes in paving the way for the successful adoption and reimbursement of cutting-edge AI-driven diagnostics. The inquiry is anchored by a detailed case study focusing on Eko Health’s SENSORA, an exemplary AI technology that has recently navigated the complex process of obtaining a Category III CPT code. By dissecting this specific instance, the paper aims to extrapolate broader principles and insights applicable to the entire landscape of AI innovation in healthcare diagnostics. It seeks to illuminate how these seemingly administrative coding decisions fundamentally underpin the clinical viability, financial sustainability, and ultimately, the transformative impact of AI on modern medicine.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Background

2.1. The Evolution of AI in Healthcare Diagnostics

Artificial intelligence, particularly sophisticated machine learning (ML) and deep learning (DL) algorithms, has demonstrated an extraordinary and rapidly expanding promise across a diverse spectrum of diagnostic domains. These include, but are not limited to, radiology, cardiology, pathology, ophthalmology, dermatology, and even areas such as genomic analysis and drug discovery. The core strength of these AI tools lies in their unparalleled ability to process and analyze massive, multi-modal datasets – ranging from medical images (X-rays, CTs, MRIs), electrocardiograms (ECGs), and pathology slides to electronic health records (EHRs), genomic sequences, and even wearable device data. By sifting through these intricate data points, AI algorithms can identify subtle patterns, anomalies, and correlations that may be imperceptible or laborious for human clinicians to discern, often achieving diagnostic accuracy levels comparable to, or in some instances, even exceeding those of highly experienced human experts.

Historically, early applications of AI in healthcare were often limited to rule-based expert systems. However, the advent of big data, increased computational power, and algorithmic breakthroughs in machine learning (especially deep learning with neural networks) have catalyzed a revolution. For instance, in radiology, advanced AI applications have been meticulously developed and rigorously tested to enhance the detection and characterization of various conditions, such as early-stage breast cancer in mammograms, malignant lung nodules in CT scans, and acute intracranial hemorrhages in head CTs. These systems can function as ‘second readers,’ improving sensitivity and specificity, or as triage tools, prioritizing critical cases.

In cardiology, AI algorithms are revolutionizing the interpretation of electrocardiograms (ECGs) and echocardiograms, capable of identifying subtle signs of heart failure, arrhythmias (like atrial fibrillation), and structural heart diseases. Beyond image and signal processing, AI is increasingly being used in pathology for automated analysis of tissue biopsies, aiding in cancer grading and diagnosis; in ophthalmology for the early detection of diabetic retinopathy and glaucoma; and in dermatology for the classification of skin lesions. Furthermore, AI’s predictive analytical capabilities are being leveraged to forecast disease progression, identify patients at high risk for certain conditions, and personalize treatment plans based on an individual’s unique genetic profile and clinical history. The evolution signifies a shift from mere computational assistance to genuine diagnostic augmentation, enhancing precision, reducing diagnostic turnaround times, and potentially extending the reach of expert diagnostics to underserved populations.

2.2. The Structure of CPT Codes

The CPT code set, meticulously maintained and updated by the American Medical Association (AMA), stands as a cornerstone of medical billing and reporting in the United States. It provides a uniform nomenclature for concisely describing medical, surgical, and diagnostic services. The structure is designed to be dynamic, allowing for the integration of new technologies and procedures while ensuring consistency across various healthcare settings. CPT codes are systematically organized into three primary categories, each serving a distinct purpose in the lifecycle of medical innovation and reimbursement:

• Category I Codes: These are the definitive and most prevalent CPT codes, representing procedures and services that are widely performed by healthcare professionals across multiple geographic areas and have attained widespread clinical acceptance. For a service or procedure to qualify for a Category I CPT code, it must meet stringent criteria, including: clinical efficacy and utility established through robust scientific evidence (e.g., peer-reviewed literature, clinical trials); widespread adoption and use by a significant number of physicians; and approval by the U.S. Food and Drug Administration (FDA) for devices or drugs when applicable. The development and maintenance of these codes involve rigorous review by the CPT Editorial Panel, a multidisciplinary body comprising physicians from various specialties and other stakeholders. These codes are typically associated with established reimbursement rates from both government (e.g., Medicare, Medicaid) and commercial payers, forming the backbone of healthcare financial transactions.

• Category II Codes: These codes are fundamentally supplemental tracking codes, primarily designed for performance measurement and quality improvement initiatives. Unlike Category I codes, they do not carry a reimbursement value. Instead, they facilitate the collection of data on the quality of care provided, specific clinical interventions, and patient outcomes. For example, a Category II code might track the percentage of patients receiving appropriate preventative screenings or follow-up care for chronic conditions. Their purpose is to reduce the administrative burden of data collection for quality reporting programs, allowing healthcare providers to efficiently report on activities that contribute to better patient care and population health management. They help in understanding trends, identifying areas for improvement, and evaluating the effectiveness of various healthcare practices.

• Category III Codes: These are temporary, alphanumeric codes specifically designated for emerging technologies, services, and procedures that do not yet meet the stringent criteria for a Category I code. The primary intent behind Category III codes is to facilitate data collection and assessment of these novel innovations, serving as a crucial preliminary step toward their potential establishment as Category I codes. They are assigned to services or procedures that show potential clinical utility but lack widespread adoption or sufficient evidence of efficacy and outcomes to warrant permanent Category I status. The criteria for Category III codes are less demanding than for Category I; they require evidence of human use, clinical relevance, and a potential for future widespread adoption. These codes often have a five-year sunset provision, meaning they must be reviewed and either converted to Category I, extended, or removed after five years. While Category III codes do not guarantee reimbursement, they provide a mechanism for payers to consider reimbursement on a case-by-case basis and, critically, allow providers to report the service, thereby generating invaluable utilization data necessary for future evidence-based decision-making regarding Category I status and definitive reimbursement policies.

2.3. The Significance of Category III Codes for AI Technologies

For nascent AI-driven diagnostic tools, obtaining a Category III CPT code represents an exceptionally critical and strategic milestone. It is far more than a mere administrative formality; it signifies a pivotal acknowledgment by the medical community and regulatory bodies of the technology’s legitimate clinical relevance and potential impact. This coding decision effectively establishes a standardized mechanism for tracking the utilization of the AI technology in real-world clinical settings, allowing for systematic data collection on its frequency of use, the types of patients it serves, and, most importantly, its associated clinical outcomes. This comprehensive data collection process is absolutely essential. It provides the robust, real-world evidence base that is stringently required to demonstrate the AI tool’s efficacy, safety, cost-effectiveness, and overall clinical utility to a degree sufficient for its eventual transition to a Category I code.

The absence of a specific CPT code renders it exceedingly difficult, if not impossible, for healthcare providers to accurately bill for new services or technologies. This creates a significant financial barrier, as providers are unlikely to widely adopt innovations for which they cannot receive appropriate compensation. Category III codes bridge this gap by enabling providers to report the use of these emerging AI diagnostics, even if initial reimbursement is variable or uncertain. This ‘coding pathway’ encourages early adoption among innovators and early adopters, allowing them to gather the necessary data. Without such a mechanism, promising AI technologies could languish in research settings, unable to gather the crucial real-world utilization data needed to prove their value and justify broader integration into mainstream clinical workflows. Therefore, Category III codes act as a vital enabling infrastructure, fostering innovation, facilitating evidence generation, and ultimately accelerating the journey of AI diagnostics from the laboratory to widespread patient benefit.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Case Study: Eko Health’s SENSORA

3.1. Overview of SENSORA

Eko Health’s SENSORA represents a groundbreaking advancement in the realm of cardiac diagnostics, embodying the transformative potential of artificial intelligence when integrated with traditional medical devices. SENSORA is an advanced AI-powered platform specifically engineered to enhance the early and accurate detection of a range of critical cardiac conditions. Its operational prowess is seamlessly integrated with Eko’s flagship digital stethoscopes, particularly the CORE 500™ Digital Stethoscope and the DUO ECG + Digital Stethoscope. This integration transforms a routine physical examination into a sophisticated diagnostic opportunity.

At its core, SENSORA utilizes highly sophisticated deep learning algorithms that have been trained on vast datasets of heart sound recordings (phonocardiograms) and electrocardiograms (ECGs). These algorithms are meticulously designed to analyze the acoustic signatures of the heart, identifying subtle abnormalities in heart murmurs, and simultaneously interpreting the electrical activity of the heart for irregularities. Specifically, SENSORA is engineered to detect key indicators of structural heart murmurs, which can signify underlying valvular heart disease; signs of low ejection fraction (EF), an indicator of systolic heart failure; and various types of arrhythmias, particularly atrial fibrillation (AFib), which is a major risk factor for stroke. The system operates by processing the sounds and electrical signals captured by the Eko stethoscope in real-time or near real-time, providing immediate interpretive feedback to the clinician.

SENSORA’s primary objective is to improve diagnostic accuracy and efficiency, particularly within primary care settings where initial cardiac screenings often occur. Historically, the detection of subtle heart conditions relies heavily on the clinician’s auscultatory skills, which can vary significantly. By providing an objective, AI-assisted analysis, SENSORA aims to reduce missed diagnoses, enable earlier intervention, and reduce unnecessary specialist referrals while simultaneously ensuring that patients requiring specialized cardiac care are identified promptly. The platform’s non-invasive nature and ease of use make it an ideal tool for widespread deployment, potentially democratizing access to advanced cardiac diagnostics beyond specialized cardiology clinics.

3.2. Acquisition of Category III CPT Code

In July 2025, Eko Health’s SENSORA achieved a significant regulatory and reimbursement milestone by being granted a Category III CPT code. While the specific code number is proprietary or yet to be widely publicized, the fact of its assignment is profoundly impactful. This decision by the AMA’s CPT Editorial Panel is a resounding acknowledgment of SENSORA’s demonstrable clinical utility, its innovative application of AI in a common clinical setting, and its potential to significantly improve patient care outcomes. The process to obtain a Category III CPT code is rigorous, requiring substantial documentation and validation. Eko Health would have presented a detailed submission to the CPT Editorial Panel, demonstrating: the technology’s unique capabilities; evidence of human use (e.g., pilot studies, clinical trials); its potential to improve diagnosis or treatment; and a clear distinction from existing coded procedures. The panel evaluates the service based on criteria that include uniqueness, clinical necessity, and potential for widespread adoption, ensuring that the code is granted to services that are truly innovative and useful.

This coding decision places SENSORA within a defined framework for reporting its use to payers. Although Category III codes do not automatically guarantee reimbursement, they provide a crucial mechanism for providers to report the service. This reporting enables payers (both commercial and governmental, like Medicare and Medicaid) to establish their own reimbursement policies. More importantly, it facilitates the systematic collection of utilization data, which is paramount for Eko Health and the broader medical community to build the necessary evidence base over time. This evidence, encompassing real-world performance, patient outcomes, and economic impact, is indispensable for SENSora to eventually transition from a temporary Category III code to a permanent Category I code, which would solidify its reimbursement landscape and accelerate its widespread adoption.

3.3. Implications for Reimbursement and Adoption

The assignment of a Category III CPT code to SENSORA is a pivotal event with far-reaching implications for its widespread adoption and financial viability within the healthcare system. Firstly, and perhaps most critically, it enables healthcare providers to bill for the AI-enhanced cardiac diagnostic services performed using SENSORA. Before a CPT code exists, such services are often considered ‘unbillable,’ meaning providers bear the full cost of the technology without a clear pathway for compensation. By creating a billing pathway, the Category III code directly addresses a significant financial barrier that often impedes the adoption of novel technologies. This ability to offset the costs associated with implementing new technologies—including the initial purchase, staff training, and ongoing maintenance—is absolutely crucial for encouraging providers to incorporate AI tools into their practices.

While Category III codes do not mandate specific reimbursement amounts and rates can vary widely among different payers, their mere existence signals to payers that the AMA has recognized the clinical value of the service. This recognition can prompt payers to establish coverage policies, even if on a case-by-case or trial basis. For Eko Health, this translates into a clearer market pathway and a more compelling value proposition for potential customers. For healthcare systems and individual clinicians, it de-risks the investment in SENSORA, making it a more attractive proposition from a financial standpoint. The financial support facilitated by this coding decision is instrumental in moving SENSORA from an innovative concept to a routinely utilized diagnostic tool, ultimately leading to improved early detection of cardiac conditions, more timely interventions, and better overall patient care outcomes, particularly in primary care settings where early screening can make the most significant difference.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Broader Implications for AI-Driven Diagnostics

4.1. Accelerating Integration into Clinical Practice

The establishment of Category III codes for AI technologies like SENSORA provides a clearly defined and structured pathway for their systematic integration into routine clinical practice. Beyond merely addressing financial barriers, these codes serve as a formal recognition of the AI tool’s legitimacy and clinical utility, fostering greater trust and acceptance among healthcare providers. When a specific code exists, it simplifies administrative processes, making it easier for clinics and hospitals to track, report, and eventually embed these services into their electronic health records (EHRs) and billing systems. This standardization reduces administrative burden, facilitates interoperability, and encourages IT departments to build necessary integrations.

Furthermore, the existence of a CPT code prompts professional medical societies, such as the American College of Cardiology or the American College of Radiology, to develop clinical guidelines that incorporate the new AI-powered diagnostic services. These guidelines, in turn, drive broader adoption by providing clarity on appropriate use cases, patient selection criteria, and expected outcomes. The coding also enables educational programs for clinicians, ensuring they are adequately trained in the effective and responsible deployment of these advanced tools. In essence, Category III codes transform AI innovations from experimental tools into recognized, reportable medical services, thereby significantly accelerating their journey from concept to widespread clinical reality and patient benefit.

4.2. Building Evidence for Category I Codes

The utilization data meticulously collected through Category III codes are absolutely instrumental in building the robust and compelling evidence base necessary for the eventual transition of AI diagnostics to Category I codes. This progression from temporary to permanent coding status is not merely an administrative upgrade; it is essential for achieving standard, predictable reimbursement rates, which are fundamental to the long-term sustainability and scalability of AI-driven diagnostics within the mainstream healthcare system. The data collected include real-world performance metrics, patient demographics, clinical scenarios where the AI tool is applied, and crucially, the associated clinical outcomes. This real-world evidence complements and extends data gathered from controlled clinical trials, providing a comprehensive picture of the AI’s efficacy and impact in diverse, heterogeneous patient populations and practice environments.

To move from Category III to Category I, AI technologies must demonstrate consistent, measurable improvements in patient outcomes, diagnostic accuracy, efficiency, and/or cost-effectiveness through large-scale, often multi-center studies. This often involves comparing AI-assisted diagnoses to traditional methods, demonstrating superiority or non-inferiority with clear benefits. The CPT Editorial Panel rigorously evaluates this evidence, often requiring peer-reviewed publications, detailed statistical analyses, and expert testimonials. Therefore, Category III codes serve as a vital ‘proving ground,’ enabling innovators to gather the necessary longitudinal data and refine their technologies based on real-world insights, ultimately paving the way for definitive coverage and widespread integration.

4.3. Enhancing Patient Care

The widespread integration of AI into diagnostic processes holds transformative potential for fundamentally enhancing patient care across multiple dimensions. Firstly, by improving diagnostic accuracy and consistency, AI can lead to earlier and more precise diagnoses, reducing the ‘diagnostic odyssey’ that many patients experience. For conditions like cancer or heart disease, early detection often translates directly into more effective treatment options, improved prognoses, and potentially life-saving interventions. Secondly, AI can significantly reduce the time to diagnosis by automating or accelerating the analysis of complex data, allowing clinicians to focus on patient interaction and critical decision-making rather than laborious data interpretation. This efficiency gain can reduce patient anxiety and allow for quicker initiation of treatment.

Thirdly, AI-driven diagnostics enable more personalized treatment plans by integrating an individual’s unique genetic, lifestyle, and clinical data to predict treatment response and risk profiles. This moves healthcare towards a precision medicine paradigm, where therapies are tailored to the individual rather than a one-size-fits-all approach. Fourthly, AI can improve accessibility to expert diagnostics, particularly in rural or underserved areas where specialist availability is limited. Remote AI analysis of images or biosignals can bring high-quality diagnostic capabilities to primary care settings or even directly to patients’ homes. The financial viability and facilitated adoption provided by Category III codes support the widespread implementation of these technologies, making these significant enhancements to patient care a scalable reality and contributing to better overall health outcomes for broader populations.

4.4. Market Development and Investment

The assignment of Category III CPT codes for emerging AI diagnostic technologies serves as a powerful signal to the broader healthcare market, including investors, technology developers, and healthcare providers. For AI startups and established companies developing these tools, securing a Category III code represents a crucial de-risking event. It indicates that the technology has passed a preliminary hurdle of clinical relevance and legitimacy as judged by the AMA, the authoritative body for medical coding. This official recognition significantly enhances the attractiveness of these companies to venture capitalists and other investors, as it suggests a clearer path to commercialization and revenue generation. Investors are more likely to fund innovations that have a defined reimbursement pathway, even if it is still nascent, compared to those that remain entirely ‘unbillable.’

Moreover, the existence of a Category III code establishes a market for the technology. Healthcare providers, knowing they can at least report the service, are more likely to consider piloting or adopting the technology, even if reimbursement is initially inconsistent. This creates an early market for AI developers, allowing them to gain traction, gather real-world data, and demonstrate value. It fosters a virtuous cycle: codes enable adoption, adoption generates data, data strengthens the evidence base, which in turn can lead to Category I codes and broader reimbursement, further fueling market growth and attracting more investment. This strategic interplay between coding, adoption, and investment is fundamental to accelerating the pace of innovation and ensuring that groundbreaking AI diagnostics can transition successfully from concept to widespread clinical impact.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Challenges and Considerations

Despite the clear advantages offered by Category III CPT codes in fostering the adoption of AI-driven diagnostics, their pathway to widespread integration is fraught with significant challenges and critical considerations that must be meticulously addressed.

5.1. Variability in Reimbursement Policies

One of the most immediate and pervasive challenges following the assignment of a Category III code is the inherent variability in reimbursement policies. While a Category III code provides a mechanism to report a service, it does not guarantee coverage or a standardized payment rate. Reimbursement decisions often vary significantly across different payers—including Medicare, Medicaid, and various commercial health insurers—as well as across different states and regions. This variability creates substantial uncertainty and administrative complexity for healthcare providers. For instance, one commercial insurer might decide to cover an AI-powered diagnostic service at a certain rate, while another might deny coverage entirely or offer a substantially lower payment. Medicare, often a trendsetter, may establish its own coverage determinations (Local Coverage Determinations or National Coverage Determinations) which can take time and may not align perfectly with commercial plans.

Furthermore, even when coverage is granted, the payment amounts for Category III codes are often determined individually by payers based on various factors, including the cost of the technology, the perceived clinical value, and internal budget considerations. This ‘patchwork’ reimbursement landscape can deter widespread adoption, as providers face unpredictable revenue streams and increased administrative burden in navigating diverse billing requirements and prior authorization processes. This inconsistency can make it challenging for healthcare organizations to justify the significant upfront investment required for AI implementation, including hardware, software licenses, and staff training. The lack of uniformity can also create health equity issues, as access to cutting-edge AI diagnostics might depend on a patient’s insurance plan or geographic location, rather than clinical necessity.

5.2. Need for Robust Clinical Validation

The transition of AI technologies from Category III to the widely accepted and consistently reimbursed Category I codes hinges entirely upon their ability to undergo rigorous, comprehensive clinical validation. This process demands substantial investment in high-quality research and extensive data collection, often requiring large-scale, multi-center prospective studies, and potentially randomized controlled trials. Unlike traditional medical devices or drugs, AI algorithms can be ‘black boxes,’ and their performance is highly dependent on the quality and representativeness of their training data.

Challenges in clinical validation for AI include: a) Data Quality and Bias: Ensuring that the training and validation datasets are diverse, representative of real-world patient populations, and free from biases (e.g., demographic, institutional, or historical biases) that could lead to discriminatory or inaccurate AI performance in specific groups. b) Generalizability: Demonstrating that an AI model performs effectively across different clinical settings, patient cohorts, and equipment variations beyond its initial development environment. c) Interpretability and Explainability (XAI): Regulatory bodies and clinicians increasingly demand transparency into AI’s decision-making process, moving beyond ‘black box’ models. This is crucial for physician trust, medical-legal accountability, and patient safety. d) Dynamic Performance: AI models may degrade over time as patient populations, diseases, or medical practices evolve, necessitating continuous monitoring and re-validation. e) Endpoint Definition: Clearly defining and measuring clinical endpoints (e.g., reduction in mortality, improved quality of life) directly attributable to AI intervention, rather than surrogate markers. The substantial resources and time required for such validation studies can be a significant bottleneck for AI developers, prolonging the journey to Category I status and definitive reimbursement.

5.3. Addressing Ethical and Regulatory Concerns

The pervasive deployment of AI in healthcare inherently raises a complex web of ethical, legal, and regulatory questions that demand meticulous consideration and proactive solutions. Failure to address these concerns can erode public trust, impede adoption, and lead to unintended negative consequences:

• Data Privacy and Security: AI models often require access to vast quantities of sensitive patient data. Ensuring robust data anonymization, de-identification, and compliance with stringent regulations like HIPAA (Health Insurance Portability and Accountability Act) in the US and GDPR (General Data Protection Regulation) in Europe is paramount. Concerns over data breaches and misuse of health data for non-medical purposes remain significant.

• Algorithmic Bias and Fairness: If AI models are trained on biased datasets (e.g., data predominantly from certain demographics, socioeconomic groups, or geographic regions), they can perpetuate and even amplify existing health disparities. This can lead to less accurate diagnoses or suboptimal treatment recommendations for underrepresented populations, raising critical questions of fairness and equity in AI. Ensuring diverse and representative training data, coupled with rigorous fairness audits, is essential.

• Transparency and Explainability (XAI): The ‘black box’ nature of many advanced AI algorithms (particularly deep learning) poses a challenge. Clinicians need to understand why an AI made a particular diagnostic recommendation to trust it, confirm its validity, and explain it to patients. Lack of transparency can hinder clinical adoption, complicate medical-legal liability, and undermine patient autonomy. Research into explainable AI (XAI) is attempting to address this, but it remains a complex area.

• Regulatory Pathways (FDA): Before an AI diagnostic can be widely used, it typically requires clearance or approval from regulatory bodies like the U.S. Food and Drug Administration (FDA). The FDA has been developing specific regulatory pathways for Software as a Medical Device (SaMD), but the rapid evolution of AI technology often outpaces traditional regulatory frameworks. Ensuring that AI models are safe, effective, and undergo appropriate pre-market review and post-market surveillance is critical.

• Medical-Legal Liability: In the event of a diagnostic error where an AI tool was involved, questions of liability arise: Is the AI developer responsible? The prescribing physician? The healthcare institution? The lack of clear legal precedents creates uncertainty for all stakeholders and necessitates new frameworks for accountability.

• Workforce Integration and Reskilling: The integration of AI will undoubtedly alter clinical workflows and the roles of healthcare professionals. There is a need for comprehensive training and education to equip clinicians with the skills to effectively use, interpret, and oversee AI tools. Concerns about potential job displacement or deskilling also need to be proactively managed through workforce planning and reskilling initiatives.

Addressing these multi-faceted challenges through collaborative efforts involving AI developers, clinicians, policymakers, regulators, and ethicists is crucial for fostering the responsible, ethical, and effective integration of AI into clinical practice and ensuring that its benefits are realized equitably across all patient populations.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Conclusion

The strategic assignment of Category III CPT codes to pioneering AI-driven diagnostic technologies, exemplarily demonstrated by the case of Eko Health’s SENSORA, undeniably represents a profoundly critical and transformative stride toward their comprehensive integration into the complex healthcare system. These temporary codes fulfill a multifaceted and indispensable role: they first and foremost facilitate the essential mechanisms for reimbursement, albeit initially variable; they concurrently support the systematic accumulation of invaluable real-world utilization data and clinical evidence; and most significantly, they meticulously pave the way for the eventual establishment of more definitive and widely accepted Category I codes, which are synonymous with standardized coverage and payment.

While the journey towards ubiquitous AI integration is inherently fraught with formidable challenges—including the persistent variability in payer reimbursement policies, the arduous and resource-intensive requirements for robust clinical validation, and the pressing need to meticulously address complex ethical, regulatory, and workforce integration concerns—the strategic and judicious use of Category III codes stands as a pivotal enabler. They act as a vital bridge, connecting groundbreaking innovation with practical clinical application. By de-risking early adoption for healthcare providers and offering a clear, albeit challenging, pathway to sustainable commercialization for AI developers, these codes are instrumental in promoting the widespread adoption and ensuring the long-term sustainability of AI-driven diagnostics within the evolving healthcare landscape. Ultimately, this structured integration is not merely about technological advancement; it is fundamentally about enhancing diagnostic accuracy, improving efficiency, expanding access to expert care, and thereby profoundly elevating the quality of patient care, significantly advancing the entire field of medical diagnostics for the benefit of global public health.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

• Ventra Health. (2025). AI in Radiology: 2025 Reimbursement Insights. Retrieved from (ventrahealth.com)

• College of American Pathologists. (2024). Digital Pathology Codes. Retrieved from (cap.org)

• American Medical Association. (2025). CPT code set facilitates development of useful AI-powered devices. Retrieved from (ama-assn.org)

• Billing Freedom. (2025). Maximize Reimbursement for AI with Category III Codes. Retrieved from (billingfreedom.com)

• AuntMinnie. (2021). New CPT code for radiology AI brings hope, but patience is needed. Retrieved from (auntminnie.com)

• American Medical Association. (2025). How do AI, VR help doctors deliver care? CPT code tells the tale. Retrieved from (ama-assn.org)

• American College of Radiology. (2025). AI in Radiology — Billing Rules of the Road. Retrieved from (acr.org)

• American College of Radiology. (2025). AMA CPT Editorial Panel Considers AI-Related Codes. Retrieved from (acr.org)

• Clinical Lab Products. (2025). Heart Disease Detection Platform May Ease Diagnostic Workloads. Retrieved from (clpmag.com)

• National Center for Biotechnology Information. (2025). Reimbursement in the age of generalist radiology artificial intelligence. Retrieved from (pmc.ncbi.nlm.nih.gov)

• American Medical Association. (2025). CPT codes offer the language to report AI-enabled health services. Retrieved from (ama-assn.org)

• American Roentgen Ray Society. (2025). ARRS and the AI Codes—Another First for Radiology. Retrieved from (arrsinpractice.org)